ID   A-375 KRAS p.G13D
AC   CVCL_UD29
SY   A-375 KRASG13D; KRAS mutant-A375 Isogenic Cell Line
DR   ATCC; CRL-1619IG-1
DR   cancercelllines; CVCL_UD29
DR   Wikidata; Q93311029
WW   https://www.atcc.org/en/support/technical-support/faqs/isogenic-cell-line-with-ras-mutation
CC   Population: Caucasian.
CC   Characteristics: Exhibits significant resistance to the BRAF inhibitors Dabrafineb and Vemurafenib when compared to its parental cell line. Can be a useful model to study the RAS-RAF-MEK-ERK-MAP kinase signaling pathway and to screen potential BRAF inhibitors and anti-cancer compounds for drug discovery and development (ATCC=CRL-1619IG-1).
CC   Doubling time: ~21 hours (ATCC=CRL-1619IG-1).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (ATCC=CRL-1619IG-1).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): ATCC=CRL-1619IG-1
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,14
ST   D16S539: 9
ST   D5S818: 12
ST   D7S820: 9
ST   TH01: 8
ST   TPOX: 8,10
ST   vWA: 16,17
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0132 ! A-375
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 13-11-18; Last updated: 02-05-24; Version: 12
//